Juno Lighting Inc Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (36)

Latest Posts

About This Stock More About This Stock
Wells Fargo Sees Little Chance Of Higher Bid For Kite Pharma
Article By: The Fly
Monday, August 28, 2017 8:05 PM EDT
Gilead and Kite Pharma have announced that the companies have entered into a definitive agreement pursuant to which the former will acquire the latter for $180 per share in cash.
In this article: GILD, JUNO, KITE, BLUE, CLLS
Read
BIO 2017 International #1: CAR-T Therapies On Solid Tumors
Article By: Rod Raynovich
Thursday, June 22, 2017 11:45 PM EDT
CAR-T shows great promise against blood cancers but challenges remain for solid tumors. Bellicum Pharmaceuticals, Bluebird bio, Cellectis SA, Juno Therapeutics, Kite Pharma and Poseida Therapeutics are some of the major companies engaged in CAR-T.
In this article: JUNO, KITE, BLUE, CLLS, BLCM
Read
Late Slide In Tech Mega-Caps Leaves Averages Mixed For Week
Article By: The Fly
Saturday, June 10, 2017 10:38 AM EDT
Stocks appeared in line for a slight weekly advance until Friday afternoon, when a sharp decline in a number of mega-cap tech stock pushed the Nasdaq down nearly 2.5% at its low point.
In this article: DFT, DHI, DLR, FOR, JWN, M, THO, VZ, CLDR, AMRI, GIII, NLNK, AAPL, AMZN, FRAN, GOOG, MSFT, YHOO, DVAX, JUNO, BABA, FB, AMBA, GLYC, KITE, BLUE, MIK, ANTM, PLAY, RDUS, LOXO, DLTH, HDS
Read
Biotech Fades After ASCO Abstract Rally
Article By: Rod Raynovich
Friday, May 26, 2017 6:29 PM EDT
Biotechs faded today now that the rush of oncology drug news cooled down. Today was dominated by the “red screen” with profit taking mainly in smaller caps and momentum driven oncology stocks.
In this article: MRK, ALNY, ALXN, BMRN, INCY, CELG, CLVS, VRTX, ZIOP, JUNO, PBYI, EPZM, GLYC, KITE, TSRO
Read
ASCO Abstracts Week: Biotech Trends And Hot Stocks
Article By: Rod Raynovich
Monday, May 22, 2017 10:58 PM EDT
Today Amgen was down over 2 % on news that its osteoporosis treatment Evenity is unlikely to win FDA approval this year because of a safety risk. Radius Health was up over 6% to $37.30 as their rival drug Tymlos was approved in April.
In this article: MRK, ALNY, IBB, INCY, REGN, AMGN, CLVS, VRTX, FBT, XBI, PUMA, JUNO, EPZM, GLYC, KITE, BLUE, RDUS
Read

PARTNER HEADLINES

Latest Tweets for $JUNO

No tweets yet!

$JUNO

Biotech Buzz Is Broken
Alpha Stockman 4/29/2015 7:09:10 PM

$KITE opened pretty good, $JUNO needs a bounce

1 to 1 of 1 comments